Pasithea Therapeutics Corp. KTTA

KTTA Company Overview

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology and biotechnology-adjacent healthcare company focused on developing treatments for central nervous system (CNS) disorders and advancing clinical and translational neuroscience initiatives. The company operates primarily in the biopharmaceutical industry, with an emphasis on psychiatric and neurological conditions, including treatment-resistant depression, post-traumatic stress disorder (PTSD), and other mental health disorders. Its business strategy combines therapeutic development with broader neuroscience-related clinical infrastructure and intellectual property initiatives.

The company’s primary value drivers have included drug development programs, clinical research capabilities, and strategic investments in emerging mental health treatment modalities. Pasithea has pursued opportunities connected to ketamine-related therapies, serotonergic compounds, and neuropsychiatric treatment technologies. Founded in 2020, the company evolved through a combination of biotechnology licensing activities, mental health clinic initiatives, and pharmaceutical development efforts. Public filings and investor disclosures indicate that the company has repositioned portions of its strategy over time toward proprietary therapeutic assets and clinical-stage development programs.